The lawsuit claims Zoetis executives presented a distorted picture of the company’s market standing, specifically touting strong sales and veterinarian adoption rates while allegedly concealing critical headwinds. According to the complaint, the company failed to disclose that demand for the canine pain treatment Librela was weakening as clinicians reacted to FDA warnings regarding neurological complications in dogs. Furthermore, the litigation asserts that Zoetis’ parasiticide, Simparica Trio, and its dermatology line—including Apoquel and Cytopoint—were losing significant market share to lower-priced or newly launched competitors.

Investors wishing to participate in the litigation or serve as a representative party must file with the court by the July 27 cutoff. While a class action has been initiated, no class has yet been certified by the court. Until certification occurs, investors are not represented by counsel unless they retain their own. Rosen Law, which has handled high-profile securities litigation, notes that shareholders are not required to serve as lead plaintiffs to participate in any eventual financial recovery.